Nintedanib

1 Indications and usage ofev: is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) ( 1.3 ) 1.1 Idiopathic Pulmonary Fibrosis OFEV is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF).

12.1 Mechanism of Action Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, colony stimulating factor 1 receptor (CSF1R), and Fms-like tyrosine kinase-3 (FLT-3). These kinases except for FLT-3 have been implicated in pathogenesis of interstitial lung diseases (ILD).

With Approximately 9–18 hours terminal plasma half-life for Nintedanib residence kinetics and Estimated 65%–77% oral systemic absorption for Nintedanib bioavailability, Nintedanib undergoes hepatic oxidation via cyp3a4/p-gp followed by renal and biliary excretion of nintedanib metabolites and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–3 hours post-dose for nintedanib.

Standard adult regimens span 150 mg/1 Capsule, 100 mg/1 Capsule. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to nintedanib or nintedanib excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2025-11-20 nintedanib spl, while community micro-logs most frequently note nausea (11.4% of reports), headache (10% of reports), diarrhea (8.7% of reports).